Advanced search
Publication Cover
Journal of Dermatological Treatment Volume 33, 2022 - Issue 3
Submit an article Journal homepage
176
Views
2
CrossRef citations to date
0
Altmetric
Articles

Long-term vemurafenib therapy in advanced melanoma patients: cutaneous toxicity and prognostic implications

Victor Desmond Mandela Skin Cancer Unit, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST), Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Meldola, Italy;b Dermatology Unit, Department of Clinical and Experimental Medicine, University of Parma, Parma, ItalyCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0003-0682-6148
ORCID Icon,
Matelda Medria Skin Cancer Unit, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST), Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Meldola, Italy
,
Ausilia Maria Manganonic Department of Dermatology, Spedali Civili di Brescia, Brescia, Italy
,
Laura Pavonic Department of Dermatology, Spedali Civili di Brescia, Brescia, Italy
,
Francesco De Rosad Immunotherapy, Cell Therapy and Biobank, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST), Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Meldola, Italy
,
Simone Riberoe Dermatologic Clinic, Department of Medical Sciences, University of Turin, Turin, ItalyORCID Iconhttps://orcid.org/0000-0002-0098-1406
ORCID Icon,
Flavia Focaf Unit of Biostatistics and Clinical Trials, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST), Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Meldola, ItalyORCID Iconhttps://orcid.org/0000-0002-5529-4769
ORCID Icon,
Daniele Andreisf Unit of Biostatistics and Clinical Trials, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST), Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Meldola, ItalyORCID Iconhttps://orcid.org/0000-0001-6686-5662
ORCID Icon,
Laura Mazzonia Skin Cancer Unit, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST), Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Meldola, Italy
,
Serena Magia Skin Cancer Unit, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST), Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Meldola, Italy
,
Francesca Farnetanig Dermatology Unit, Surgical, Medical and Dental Department of Morphological Sciences related to Transplant, Oncology and Regenerative Medicine, University of Modena and Reggio Emilia, Modena, ItalyORCID Iconhttps://orcid.org/0000-0001-7088-9077
ORCID Icon,
Marco Pallah Unit of Melanoma, Cancer Immunotherapy & Innovative Therapies Unit, Istituto Nazionale Tumori “Fondazione G. Pascale”, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Naples, ItalyORCID Iconhttps://orcid.org/0000-0001-8901-0974
ORCID Icon,
Paola Ulivii Biosciences Laboratory, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST), Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Meldola, ItalyORCID Iconhttps://orcid.org/0000-0002-4334-9662
ORCID Icon &
Ignazio Stanganellia Skin Cancer Unit, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST), Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Meldola, Italy;b Dermatology Unit, Department of Clinical and Experimental Medicine, University of Parma, Parma, Italy
 show all
Pages 1368-1375 | Received 17 Jun 2020, Accepted 27 Aug 2020, Published online: 09 Sep 2020

References

  • Long GV, Menzies AM, Nagrial AM, et al. Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma. J Cin Oncol. 2011;29:1239–1246.
  • Ugurel S, Röhmel J, Ascierto PA, et al. Survival of patients with advanced metastatic melanoma: the impact of novel therapies-update 2017. Eur J Cancer. 2017;83:247–257.
  • Levêque D. Off-label use of targeted therapies in oncology. World J Clin Oncol. 2016;7:253–257.
  • McArthur GA, Chapman PB, Robert C, et al. Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study. Lancet Oncol. 2014;15:323–332.
  • Larkin J, Del Vecchio M, Ascierto PA, et al. Vemurafenib in patients with BRAF(V600) mutated metastatic melanoma: an open-label, multicentre, safety study. Lancet Oncol. 2014;15:436–444.
  • Balch CM, Gershenwald JE, Soong SJ, et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol. 2009;27:6199–6206.
  • Long GV, Eroglu Z, Infante J, et al. Long-term outcomes in patients with BRAF V600-mutant metastatic melanoma who received dabrafenib combined with trametinib. J Clin Oncol. 2018;36:667–673.
  • Anforth R, Fernandez-Peñas P, Long GV. Cutaneous toxicities of RAF inhibitors. Lancet Oncol. 2013;14:e11–e18.
  • Anforth R, Carlos G, Clements A, et al. Cutaneous adverse events in patients treated with BRAF inhibitor-based therapies for metastatic melanoma for longer than 52 weeks. Br J Dermatol. 2015;172:239–243.
  • Chapman PB, Hauschild A, Robert C, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011;364:2507–2516.
  • Hauschild A, Grob JJ, Demidov LV, et al. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet. 2012;380:358–365.
  • Cohen PR, Bedikian AY, Kim KB. Appearance of new vemurafenib-associated melanocytic nevi on normal-appearing skin: case series and a review of changing or new pigmented lesions in patients with metastatic malignant melanoma after initiating treatment with vemurafenib. J Clin Aesthet Dermatol. 2013;6:27–37.
  • Haenssle HA, Kraus SL, Brehmer F, et al. Dynamic changes in nevi of a patient with melanoma treated with vemurafenib: importance of sequential dermoscopy. Arch Dermatol. 2012;148:1183–1185.
  • Perier-Muzet M, Thomas L, Poulalhon N, et al. Melanoma patients under vemurafenib: prospective follow-up of melanocytic lesions by digital dermoscopy. J Invest Dermatol. 2014;134:1351–1358.
  • Stanganelli I, Longo C, Mazzoni L, et al. Integration of reflectance confocal microscopy in sequential dermoscopy follow-up improves melanoma detection accuracy. Br J Dermatol. 2015;172:365–371.
  • Farnetani F, Scope A, Mazzoni L, et al. A comparative dermoscopic and reflectance confocal microscopy study of naevi and melanoma with negative pigment network. J Eur Acad Dermatol Venereol. 2019;33:2273–2282.
  • Peccerillo F, Mandel VD, Di Tullio F, et al. Lesions mimicking melanoma at dermoscopy confirmed basal cell carcinoma: evaluation with reflectance confocal microscopy. Dermatology. 2019;235:35–44.
  • Ruini C, Manfredini M, Pellacani G, et al. Confocal microscopy characterization of BRAFV600E mutated melanomas. Melanoma Res. 2015;25:367–371.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.